ArticleCurrent chemical genomics2011
Targets in epigenetics: inhibiting the methyl writers of the histone code.
Article in Current chemical genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs.RSC medicinal chemistry · 2025Article
- Photoregulation of PRMT-1 Using a Photolabile Non-Canonical Amino Acid.Molecules (Basel, Switzerland) · 2021Article
- Glutathionylation Decreases Methyltransferase Activity of PRMT5 and Inhibits Cell Proliferation.Molecular & cellular proteomics : MCP · 2020Article
- Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.Current genomics · 2017Review
- DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.Biomolecules · 2017Review
- Small Molecule Inhibitors of Protein Arginine Methyltransferases.Expert opinion on investigational drugs · 2016Review
- Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.Scientific reports · 2015Article
- Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.Journal of translational medicine · 2015Article
- Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity.Drug discovery today. Technologies · 2015Review
- Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.Oncotarget · 2015Article
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.Cellular and molecular life sciences : CMLS · 2015Review
- Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.Journal of cancer prevention · 2015Article
- Kinetic mechanism of protein N-terminal methyltransferase 1.The Journal of biological chemistry · 2015Article
- Selective inhibitors of protein methyltransferases.Journal of medicinal chemistry · 2015Article
- TLR2 promoter hypermethylation creates innate immune dysbiosis.Journal of dental research · 2015Article
- Structure-activity relationship studies of SETD8 inhibitors.MedChemComm · 2014Article
- Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.Journal of medicinal chemistry · 2014Article
- A gain-of-function mouse model identifies PRMT6 as a NF-κB coactivator.Nucleic acids research · 2014Article
- Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications.Reproductive sciences (Thousand Oaks, Calif.) · 2014Article
- Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.Molecular & cellular proteomics : MCP · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Growing evidence suggests that protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs) are associated with the development of various human diseases, including cancer, inflammation, and psychiatric disorders. Given the significant role of these proteins in human disease, efforts to discover selective small-molecule inhibitors of these enzymes are quickly gaining momentum. In this review, we focus on the recent progress in the discovery of selective PKMT and PRMT inhibitors. A future perspective on developing methyltransferase inhibitors is also offered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.